IL265232A - Uses of lysyl oxidase-like inhibitor 2 - Google Patents

Uses of lysyl oxidase-like inhibitor 2

Info

Publication number
IL265232A
IL265232A IL265232A IL26523219A IL265232A IL 265232 A IL265232 A IL 265232A IL 265232 A IL265232 A IL 265232A IL 26523219 A IL26523219 A IL 26523219A IL 265232 A IL265232 A IL 265232A
Authority
IL
Israel
Prior art keywords
inhibitor
lysyl oxidase
lysyl
oxidase
Prior art date
Application number
IL265232A
Other languages
English (en)
Hebrew (he)
Original Assignee
Pharmakea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmakea Inc filed Critical Pharmakea Inc
Publication of IL265232A publication Critical patent/IL265232A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrrole Compounds (AREA)
IL265232A 2016-09-07 2019-03-06 Uses of lysyl oxidase-like inhibitor 2 IL265232A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662384542P 2016-09-07 2016-09-07
US201762509460P 2017-05-22 2017-05-22
PCT/US2017/050331 WO2018048942A1 (en) 2016-09-07 2017-09-06 Uses of a lysyl oxidase-like 2 inhibitor

Publications (1)

Publication Number Publication Date
IL265232A true IL265232A (en) 2019-05-30

Family

ID=61561650

Family Applications (1)

Application Number Title Priority Date Filing Date
IL265232A IL265232A (en) 2016-09-07 2019-03-06 Uses of lysyl oxidase-like inhibitor 2

Country Status (13)

Country Link
US (3) US11793797B2 (enExample)
EP (3) EP3509594B1 (enExample)
JP (1) JP7097874B2 (enExample)
KR (2) KR102615565B1 (enExample)
CN (2) CN117180280A (enExample)
AU (1) AU2017324444A1 (enExample)
BR (1) BR112019004513A2 (enExample)
CA (1) CA3036062A1 (enExample)
ES (1) ES3015717T3 (enExample)
IL (1) IL265232A (enExample)
MA (1) MA46203A (enExample)
MX (1) MX2019002612A (enExample)
WO (1) WO2018048942A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034891B1 (ru) 2015-03-06 2020-04-02 Фармакеа, Инк. Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение
EP3265445B1 (en) * 2015-03-06 2021-05-05 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
AU2017218889A1 (en) 2016-02-09 2018-08-30 Pharmakea, Inc. Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof
CA3036064A1 (en) 2016-09-07 2018-03-15 Pharmakea, Inc. Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
WO2018048942A1 (en) 2016-09-07 2018-03-15 Pharmakea, Inc. Uses of a lysyl oxidase-like 2 inhibitor
WO2019178329A1 (en) * 2018-03-16 2019-09-19 The Regents Of The University Of Michigan Compositions and methods for treating graves disease
CN112441916A (zh) * 2019-08-29 2021-03-05 广东药科大学 新型苯乙酸衍生物、其制备方法及其作为药物的用途
EP4031124A4 (en) * 2019-09-20 2024-01-24 Reneo Pharmaceuticals, Inc. Use of a ppar-delta agonist in the treatment of kidney disease
WO2021086973A2 (en) * 2019-10-28 2021-05-06 University Of Iowa Research Foundation Formulation for delivery of lubricin gene
CN110714016B (zh) * 2019-11-29 2021-08-20 长沙学院 Jnk基因及其作为鱼类细菌性肠炎诊断分子标记物和治疗靶点的应用
CN112662763A (zh) * 2020-03-10 2021-04-16 博尔诚（北京）科技有限公司 一种检测常见两性癌症的探针组合物
US20240041825A1 (en) * 2020-12-03 2024-02-08 Delta 4 Gmbh Saroglitazar and myristic acid for use in the treatment of focal segmental glomerulosclerosis (fsgs)
US20250249013A1 (en) * 2022-04-08 2025-08-07 The Regents Of The University Of California Combination metabolic-epigenetic treatment for early lung cancer

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
IE56702B1 (en) 1982-12-01 1991-11-06 Usv Pharma Corp Antiinflammatory antiallergic compounds
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5250532A (en) 1991-04-11 1993-10-05 Dowelanco 3,4,N-trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
US7125880B1 (en) 1995-06-06 2006-10-24 Pfizer Inc. Corticotropin releasing factor antagonists
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
BR0107662A (pt) 2000-01-18 2002-11-19 Pfizer Prod Inc Antagonistas do fator de liberação de corticotropina
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
FI20030030A0 (fi) 2003-01-09 2003-01-09 Orion Corp Uusia yhdisteitä
SI1638551T1 (sl) 2003-05-19 2012-04-30 Irm Llc Imunosupresivne spojine in sestavki
WO2005082370A1 (en) 2004-01-29 2005-09-09 Pfizer Products Inc. Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders
EP1727788B1 (en) 2004-03-12 2010-07-28 Eli Lilly And Company Opioid receptor antagonists
EP1735268B1 (en) 2004-03-15 2012-02-15 Eli Lilly And Company Opioid receptor antagonists
AU2005238386A1 (en) 2004-04-30 2005-11-10 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof as an MMP-13 inhibitor
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
MX2007002460A (es) 2004-09-10 2007-05-04 Pfizer Prod Inc Metodos para tratar trastornos del humor utilizando derivados azabiciclicos de piridiloximetilo y benzisoxazol.
US20070270430A1 (en) 2004-09-10 2007-11-22 Pfzer Inc Methods of Treating Cognitive Disorders Using Pyridyloxymethyl and Benzisoxazole Azabicyclic Derivatives
WO2006052546A2 (en) 2004-11-04 2006-05-18 Neurogen Corporation Pyrazolylmethyl heteroaryl derivatives
DE102004056226A1 (de) 2004-11-22 2006-05-24 Burchardt, Elmar Reinhold, Dr.Dr. Neuartige Inhibitoren der Lysyloxidase
ATE440091T1 (de) 2005-01-31 2009-09-15 Merck & Co Inc Antidiabetische bicyclische verbindungen
AR055041A1 (es) 2005-03-23 2007-08-01 Merck Frosst Canada Ltd Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
AU2006279211A1 (en) 2005-08-11 2007-02-15 Merck Frosst Canada Ltd Novel substituted 1,2,3-triazolylmethyl-benzothiophene or -indole and their use as leukotriene biosynthesis inhibitors
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
ITMI20051943A1 (it) 2005-10-14 2007-04-15 Procos Spa Processo di risoluzione anantiomerica di 2-aminometil-pirrolidine 1-sostitute per ammidazione in presenza di lipasi
US20070225285A1 (en) 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070219206A1 (en) 2005-11-04 2007-09-20 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
EP1978966A4 (en) 2006-01-23 2010-11-10 Amira Pharmaceuticals Inc TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE
GB0614579D0 (en) 2006-07-21 2006-08-30 Black James Foundation Pyrimidine derivatives
WO2008020799A1 (en) 2006-08-18 2008-02-21 Astrazeneca Ab Thienopyrimidin-4-one and thienopyridazin-7-one derivatives as mch rl antagonists
US20100074897A1 (en) * 2006-12-01 2010-03-25 University Of Utah Research Foundation Methods and Compositions related to HIF-1 alpha
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
SI2185198T1 (sl) 2007-08-02 2015-04-30 Gilead Biologics, Inc. Inhibitorji LOX in LOXL2 ter njihova uporaba
EP2458995A1 (en) 2009-07-28 2012-06-06 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
EP2467162A4 (en) * 2009-08-21 2013-10-02 Gilead Biologics Inc THERAPEUTIC PROCESSES AND RELATED COMPOSITIONS
SG183174A1 (en) 2010-02-04 2012-09-27 Gilead Biologics Inc Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
WO2011097594A2 (en) 2010-02-08 2011-08-11 Kinagen, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
CN103002742B (zh) 2010-03-05 2016-07-13 卡尔约药物治疗公司 核转运调节剂及其应用
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
PH12013501001A1 (en) 2010-11-19 2019-09-02 Incyte Holdings Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
CN104394869A (zh) 2011-10-20 2015-03-04 葛兰素史密斯克莱有限责任公司 用作沉默调节蛋白调节剂的取代的双环氮杂杂环化合物和类似物
US9701658B2 (en) 2012-04-25 2017-07-11 Raqualia Pharma Inc. Amide derivatives as TTX-S blockers
KR20150074179A (ko) * 2012-10-30 2015-07-01 길리애드 사이언시즈, 인코포레이티드 리실 옥시다제-유사 2 (loxl2)와 관련된 치료 및 진단 방법
CN104854086B (zh) 2012-12-18 2017-06-27 Ea制药株式会社 杂环酰胺衍生物和含有其的药物
AU2015298491A1 (en) 2014-02-14 2016-09-01 The University Of British Columbia Modulators of caspase-6
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
CR20170367A (es) 2015-02-15 2017-09-12 Hoffmann La Roche Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
EA034891B1 (ru) * 2015-03-06 2020-04-02 Фармакеа, Инк. Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение
EP3265445B1 (en) 2015-03-06 2021-05-05 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
WO2018048942A1 (en) 2016-09-07 2018-03-15 Pharmakea, Inc. Uses of a lysyl oxidase-like 2 inhibitor
CA3036064A1 (en) 2016-09-07 2018-03-15 Pharmakea, Inc. Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making

Also Published As

Publication number Publication date
US20190192495A1 (en) 2019-06-27
CN109922803A (zh) 2019-06-21
US11793797B2 (en) 2023-10-24
EP3509594C0 (en) 2025-02-26
CA3036062A1 (en) 2018-03-15
JP7097874B2 (ja) 2022-07-08
KR20230162996A (ko) 2023-11-29
JP2019526589A (ja) 2019-09-19
KR102615565B1 (ko) 2023-12-18
EP3509594B1 (en) 2025-02-26
CN117180280A (zh) 2023-12-08
BR112019004513A2 (pt) 2019-06-18
US20210177820A1 (en) 2021-06-17
EP3509594A1 (en) 2019-07-17
EP4385571A2 (en) 2024-06-19
EP4385571A3 (en) 2024-08-28
MA46203A (fr) 2019-07-17
EP4052707A1 (en) 2022-09-07
AU2017324444A1 (en) 2019-04-11
US20240415824A1 (en) 2024-12-19
KR20190065265A (ko) 2019-06-11
WO2018048942A1 (en) 2018-03-15
MX2019002612A (es) 2019-08-21
ES3015717T3 (en) 2025-05-07
EP3509594A4 (en) 2020-05-06
CN109922803B (zh) 2023-09-22

Similar Documents

Publication Publication Date Title
IL265232A (en) Uses of lysyl oxidase-like inhibitor 2
IL254236A0 (en) Fluorine-converted lysyl oxidase-like 2 inhibitors and their uses
EP3265445A4 (en) Lysyl oxidase-like 2 inhibitors and uses thereof
IL301591B1 (en) Solid forms and combination preparations containing beta-lactamase inhibitor and uses thereof
IL262398A (en) Biosynthesis of cannabinoid prodrugs
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
EP3317258A4 (en) LYSYL OXIDASE LIKE 2 INHIBITORS AND USES THEREOF
IL269711A (en) ASK1 inhibitory compounds and their uses
EP3325462A4 (en) INHIBITORS OF LYSYL OXIDASE-LIKE 2 AND USES OF SAID INHIBITORS
GB201705971D0 (en) Inhibitor compounds
IL265192A (en) Crystalline forms of lysyl oxidase inhibitor-like 2 and methods of preparation
IL273727A (en) Lysyl oxidase inhibitors
PL3185911T3 (pl) Zestaw do znakowania radioizotopowego 68CA zawierający inhibitor metalu
EP3699245A4 (en) INK SET
PL3543240T3 (pl) Inhibitor urat1 i jego stosowanie
ZA201704301B (en) Microencapsulated nitrification inhibitor compositions
EP3562487A4 (en) METALLOENZYME INHIBITORS
ZA201901773B (en) Pde4 inhibitor
SG10202006699XA (en) Inhibition of allergic reaction using an il-33 inhibitor
FR3028789B3 (fr) Structure anti-detachement d'une boite a outils
ZA201807056B (en) Conjugated c1 esterase inhibitor and uses thereof
EP3345974C0 (en) Pearlescent pigments obtained by wet oxidation
FR3025542B3 (fr) Agencement d'un espace de salle de bain
HK40009578A (en) Uses of a lysyl oxidase-like 2 inhibitor
GB201706574D0 (en) Corrosion inhibitor